David Tulasne

Lille, 59000, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 55 publications

Derepression of the epithelial transcription factor GRHL2 promotes direct hepatocyte-to-cholangiocyte transdifferentiation.

Derepression of the epithelial transcription factor GRHL2 promotes direct hepatocyte-to-cholangiocyte transdifferentiation.

Journal: PLoS biology
Published: January 24, 2025

Comprehensive map of the regulatory network triggered by MET exon 14 skipping reveals important involvement of the RAS-ERK signaling pathway.

Comprehensive map of the regulatory network triggered by MET exon 14 skipping reveals important involvement of the RAS-ERK signaling pathway.

Journal: Cell death & disease
Published: October 28, 2024

A coregulatory influence map of glioblastoma heterogeneity and plasticity.

A coregulatory influence map of glioblastoma heterogeneity and plasticity.

Journal: NPJ precision oncology
Published: September 22, 2024

MET variants with activating N-lobe mutations identified in hereditary papillary renal cell carcinomas still require ligand stimulation.

MET variants with activating N-lobe mutations identified in hereditary papillary renal cell carcinomas still require ligand stimulation.

Journal: Molecular oncology
Published: March 14, 2024

Functional interaction between receptor tyrosine kinase MET and ETS transcription factors promotes prostate cancer progression.

Functional interaction between receptor tyrosine kinase MET and ETS transcription factors promotes prostate cancer progression.

Journal: Molecular oncology
Published: November 23, 2023

MET variants with activating N-lobe mutations identified in hereditary papillary renal cell carcinomas still require ligand stimulation.

MET variants with activating N-lobe mutations identified in hereditary papillary renal cell carcinomas still require ligand stimulation.

Journal: bioRxiv : the preprint server for biology
Published: November 15, 2023

Recording and classifying MET receptor mutations in cancers.

Recording and classifying MET receptor mutations in cancers.

Journal: eLife
Published: September 14, 2023

Prolonging lung cancer response to EGFR inhibition by targeting the selective advantage of resistant cells.

Prolonging lung cancer response to EGFR inhibition by targeting the selective advantage of resistant cells.

Journal: Nature communications
Published: August 09, 2023

Transforming properties of MET receptor exon 14 skipping can be recapitulated by loss of the CBL ubiquitin ligase binding site.

Transforming properties of MET receptor exon 14 skipping can be recapitulated by loss of the CBL ubiquitin ligase binding site.

Journal: FEBS letters
Published: January 19, 2023

MET exon 14 skipping mutation is a hepatocyte growth factor (HGF)-dependent oncogenic driver in vitro and in humanised HGF knock-in mice.

MET exon 14 skipping mutation is a hepatocyte growth factor (HGF)-dependent oncogenic driver in vitro and in humanised HGF knock-in mice.

Journal: Molecular oncology
Published: June 22, 2022

3-phosphoinositide-dependent protein kinase 1 (PDK1) mediates crosstalk between Src and Akt pathways in MET receptor signaling.

3-phosphoinositide-dependent protein kinase 1 (PDK1) mediates crosstalk between Src and Akt pathways in MET receptor signaling.

Journal: FEBS letters
Published: August 23, 2021

Novel germline MET pathogenic variants in French patients with papillary renal cell carcinomas type I.

Novel germline MET pathogenic variants in French patients with papillary renal cell carcinomas type I.

Journal: Human mutation
Published: May 24, 2021
Showing 1-12 of 55

Last Updated: 09/26/2026